Skip Navigation

Cardiovascular Research 2005 67(1):97-105; doi:10.1016/j.cardiores.2005.03.001
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fraccarollo, D.
Right arrow Articles by Bauersachs, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fraccarollo, D.
Right arrow Articles by Bauersachs, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction

Daniela Fraccarollo*,1, Paolo Galuppo1, Isabel Schmidt, Georg Ertl and Johann Bauersachs

Medizinische Klinik I, Universitätsklinikum, Julius-Maximilians-Universität Würzburg, Würzburg, Germany

* Corresponding author. Medizinische Klinik I, Universitätsklinikum, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany. Tel.: +49 931 201 36301; telefax: +49 931 201 36302. Email address: fraccaroll_d{at}medizin.uni-wuerzburg.de

Objectives: The mechanisms underlying the clinical benefits of mineralocorticoid receptor antagonism in patients with left ventricular (LV) dysfunction and heart failure (CHF) after myocardial infarction (MI) are poorly understood.

Methods: We investigated whether long-term (9 weeks) aldosterone antagonism with eplerenone (100 mg/kg/day) provides additional benefit to angiotensin II type 1 (AT1) receptor inhibition with irbesartan (50 mg/kg/day) on cardiac remodeling after MI in rats.

Results: Eplerenone monotherapy, like AT1 receptor blockade, significantly reduced LV end-diastolic pressure (LVEDP), end-systolic volume (LVESV) and end-diastolic volume (LVEDV) compared to placebo. Improvement of LV dilation by aldosterone antagonism was associated with a significant reduction of increased AT1 receptor, angiotensin-converting enzyme (ACE) and endothelin-1 gene expression in the noninfarcted LV myocardium. Combination therapy with irbesartan led to a substantial further leftward shift of the LV pressure–volume curve and decrease in LVEDP, LVESV and LVEDV. Moreover, combination therapy significantly improved LV systolic and diastolic function and reversed LV alterations of {alpha}- and β-myosin heavy-chain isoforms, ANF and SERCA2 ATPase expression more effectively than monotherapies. LV collagen type I and type III expression as well as interstitial fibrosis were substantially increased in placebo CHF rats, similarly decreased by eplerenone and irbesartan, and further reduced by eplerenone/irbesartan. However, no additive effects of eplerenone/irbesartan on myocardial AT1 receptor, ACE and endothelin-1 mRNAs were observed.

Conclusions: Aldosterone receptor antagonism provides additional benefit to AT1 receptor blockade on LV function and remodeling associated with improvement of molecular alterations responsible for progressive contractile dysfunction post-MI.

KEYWORDS Aldosterone; Angiotensin; Remodeling; Myocardial infarction; Heart failure

1 Both authors contributed equally to the present study.

Time for primary review 34 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
S. A Reini, G. Dutta, C. E Wood, and M. Keller-Wood
Cardiac corticosteroid receptors mediate the enlargement of the ovine fetal heart induced by chronic increases in maternal cortisol
J. Endocrinol., August 1, 2008; 198(2): 419 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
X. Xu, W. Wan, L. Ji, S. Lao, A. S. Powers, W. Zhao, J. M. Erikson, and J. Q. Zhang
Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats
Cardiovasc Res, June 1, 2008; 78(3): 523 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. K.Y. Chan, J. E. Sanderson, T. Wang, W. Lam, G. Yip, M. Wang, Y.-Y. Lam, Y. Zhang, L. Yeung, E. B. Wu, et al.
Aldosterone Receptor Antagonism Induces Reverse Remodeling When Added to Angiotensin Receptor Blockade in Chronic Heart Failure
J. Am. Coll. Cardiol., August 14, 2007; 50(7): 591 - 596.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Stas, A. Whaley-Connell, J. Habibi, L. Appesh, M. R. Hayden, P. R. Karuparthi, M. Qazi, E. M. Morris, S. A. Cooper, C. D. Link, et al.
Mineralocorticoid Receptor Blockade Attenuates Chronic Overexpression of the Renin-Angiotensin-Aldosterone System Stimulation of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Cardiac Remodeling
Endocrinology, August 1, 2007; 148(8): 3773 - 3780.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
Y.-M. Kang, Z.-H. Zhang, R. F. Johnson, Y. Yu, T. Beltz, A. K. Johnson, R. M. Weiss, and R. B. Felder
Novel Effect of Mineralocorticoid Receptor Antagonism to Reduce Proinflammatory Cytokines and Hypothalamic Activation in Rats With Ischemia-Induced Heart Failure
Circ. Res., September 29, 2006; 99(7): 758 - 766.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.